Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a synthetic lethal program in a deal worth more than 500 million euros ($570 ...
AMSTERDAM and LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment ...
Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer therapies for tumours that rely on the alternative lengthening of telomeres ...
Naarden, the Netherlands and Stevenage, UK, 01 October 2025 – Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, today announces the ...
Boehringer Ingelheim and Tessellate Bio have entered into a partnership worth over €500m to develop oral precision medicines for hard-to-treat cancers. The research collaboration and global licence ...
Boehringer Ingelheim, is a biopharmaceutical company, and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research ...
FREMONT, Calif.--(BUSINESS WIRE)--Terafina Inc., a proactive omnichannel digital sales platform that drives guided client experiences to boost sales conversion, announced today the release of Terafina ...
INGELHEIM, Germany and AMSTERDAM, April 23, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback